MitoRx Therapeutics Logo
Our Science
Pipeline
Our Team
SAB
News
Contact
HomeOur SciencePipelineOur TeamContact

MitoRx Therapeutics appoints Xavier Jacq as CSO

1/5/2025

May 1, 2025

‍Harwell, Oxford, May 1, 2025, MitoRxTherapeutics Limited (MitoRx), a platform biotech companydeveloping novel mitochondrial-targeted persulfide modifiers, today announcesthe appointment of Xavier Jacq as Chief Scientific Officer (CSO).

Xavier is a world-class scientistwith extensive experience in small molecule drug development and mitochondrialbiology. He was most recently CSO at Moa Technologies in Oxford. Xavierpreviously held scientific leadership positions at Almac and MissionTherapeutics, and project leadership positions at Kudos and Sanofi. He has beena company founder, helping raise investment, building labs and drug discoveryteams from scratch, and helping companies successfully exit throughacquisition.

The new CSO significantlystrengthens the MitoRx team as it builds towards clinical candidate nominationin its lead indication of the treatment of obesity and also develops a pipelineof discrete novel persulfide modifiers for a range of degenerative diseases.

“Welcoming Xavier to MitoRx cementsour position as the leading biotech company developing mitochondrial-targetedtherapeutics,” said Jon Rees, CEO, MitoRx.

“MitoRx is developing an innovative technology to restoremitochondrial metabolic pathways that are suppressed in a number of pathologiesand in ageing. The prospect of being able to contribute to restoring metabolicfunction for patients with unmet medical needs is such an exciting opportunitythat I had to join,” saidXavier Jacq, CSO, MitoRx. “MitoRx is a company with an enthusiastic andexperienced team. This was also an essential factor in my decision to joinMitoRx. We now have the potential to make a significant difference a largenumber of patients with degenerative diseases.” 

For more information please contact:

Neil Hunter
Hunter PR
neiljameshunter@gmail.com
+44 7821 255568

About MitoRx

MitoRx’s mission is to develop a newclass of medicine restoring normal metabolism by correcting impairedsulfide-signaling in obesity-related indications. Located in Harwell, Oxford, MitoRxhas raised USD 8 million in seed financing from investors including the UKInnovation & Science Seed Fund, the Fink Family Office, Wren Capital, OxfordTechnology Management, Empirical Ventures, the Science Angel Syndicate Network,Panacea Innovation Ventures, Longevitytech.fund, as well as angel investors.For more information visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn.

MitoRx Therapeutics Logo

Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration.

Mail Icon

info@mitorxtherapeutics.com

Phone Icon

+44 1235 838631

Follow Us
About Us
HomeOur scienceOur teamContactNews
Legal
Privacy policyTerms of use
© Copyright 2021 MitoRx Therapeutics Limited - All Rights Reserved
9400 Garsington Road, Oxford Business Park Oxford OX4 2HN
Registered in England and Wales Company No. 13237941
Website by Stefan Benfield